Figure 1 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib

Figure 1 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib

<p>Patient prescreening/screening and enrollment. *One (0.3%) patient was enrolled based on local testing in a protocol violation. LBx-negative, negative for <i>MET</i>ex14 skipping in LBx; LBx-positive, positive for <i>MET</i>ex14 skipping in LBx; LBx<sub>N/A<...

Description complète

Enregistré dans:
Détails bibliographiques
Auteur principal: Christian Rolfo (17314293) (author)
Autres auteurs: Aurora O’Brate (21632380) (author), Christoph Menzel (21632383) (author), Rolf Bruns (15331351) (author), Dilafruz Juraeva (21468025) (author), Christopher Stroh (16494599) (author), Andreas Johne (15331354) (author), Paul K. Paik (15055771) (author)
Publié: 2025
Sujets:
Cancer
Cancer Detection and Diagnosis
Therapeutic Research and Development
Clinical Research and Trials
Methods and Technology
Biomarkers
Clinical Trial Results
Phase II clinical trials
Liquid Biopsy
Lung Cancer
Small Molecule Agents
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires